| 0 (0%) | 12-27 00:24 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.71 | 1-year : | 1.95 |
| Resists | First : | 1.47 | Second : | 1.66 |
| Pivot price | 1.24 |
|||
| Supports | First : | 1.14 | Second : | 0.95 |
| MAs | MA(5) : | 1.22 | MA(20) : | 1.3 |
| MA(100) : | 1.54 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 14.6 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 13.71 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PLRX ] has closed above bottom band by 24.4%. Bollinger Bands are 65.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.24 | 1.24 - 1.24 |
| Low: | 1.18 - 1.18 | 1.18 - 1.19 |
| Close: | 1.2 - 1.21 | 1.21 - 1.22 |
Sun, 21 Dec 2025
Why PLRX stock could see breakout soon - Trade Signal Summary & Precise Buy Zone Identification - Улправда
Mon, 08 Dec 2025
Pliant Therapeutics Announces Departure of Chief Medical Officer - TipRanks
Fri, 05 Dec 2025
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), uniQure (QURE) and Medtronic (MDT) - The Globe and Mail
Thu, 04 Dec 2025
Pliant Therapeutics (Nasdaq: PLRX) reports interim PLN-101095 data with 1 CR, 3 PRs - Stock Titan
Mon, 01 Dec 2025
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewswire
Fri, 10 Oct 2025
J.P. Morgan Downgrades Pliant Therapeutics(PLRX.US) to Sell Rating - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 61 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 84.6 (%) |
| Shares Short | 3,990 (K) |
| Shares Short P.Month | 3,720 (K) |
| EPS | -2.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -64.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -0.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|